Novo Nordisk says Ozempic copycats in China may be delayed
Danish pharmaceutical company Novo Nordisk said generic versions of its diabetes drug Ozempic could be delayed in China until 2027 due to regulatory data protection rights. The patent for semaglutide, …
Novo Nordisk says Ozempic copycats in China may be delayed Read More
